Xenon Reports Third Quarter 2025 Financial Results & Business Update
Xenon Pharmaceuticals Inc. - Common Shares (XENE)
Last xenon pharmaceuticals inc. - common shares earnings: 11/5 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.xenon-pharma.com
Company Research
Source: GlobeNewswire
– Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete – Phase 3 X-NOVA2 and X-NOVA3 studies in MDD & Phase 3 X-CEED study in BPD continuing to recruit – Phase 1 Nav1.7 & Kv7 studies underway – Tucker Kelly appointed as Chief Financial Officer, bringing extensive strategic commercial finance experience in anticipation of the azetukalner launch – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today reported financial results for the third quarter ended September 30, 2025 and provided a business update. “We are entering an important, catalyst-rich period for Xenon. We recently completed randomization of 380 patients in our Phase 3 X-TOLE2 study of azetukal
Show less
Read more
Impact Snapshot
Event Time:
XENE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XENE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XENE alerts
High impacting Xenon Pharmaceuticals Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
XENE
News
- Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025 [Canadian Business Journal (Canada)]Canadian Business Journal
- Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025GlobeNewswire
- Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025 [Canadian Business Journal (Canada)]Canadian Business Journal
XENE
Earnings
- 11/3/25 - Beat
XENE
Sec Filings
- 12/5/25 - Form 144
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- XENE's page on the SEC website